Acasti Pharma Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Note 11 - Derivative Warrant Liabilities (Tables)

Note 11 - Derivative Warrant Liabilities (Tables)

12 Months Ended

Mar. 31, 2018

Statement Line Items [Line Items]

Disclosure of maturity analysis for derivative financial liabilities [text block]

Warrant liabilities issued December 27, 2017
							Thirteen-month period				Month ended				Twelve-month period
			March 31, 2018				Ended, March 31, 2017				March 31, 2017 (Unaudited)				ended February 28, 2017 (Unaudited)
			$				$				$				$

Balance – beginning of period			-				-				-				-
Issued during period (note 13b)			5,873				-				-				-
Change in fair value of derivative warrant liabilities			532				-				-				-
Balance – end of period			6,405				-				-				-

Warrant liabilities issued December 3, 2013 1
							Thirteen-month period				Month ended				Twelve-month period
			March 31, 2018				ended, March 31, 2017				March 31, 2017 (Unaudited)				ended February 28, 2017 (Unaudited)
			$				$				$				$

Balance – beginning of period			209				156				187				156
Change in fair value of derivative warrant liabilities			(188	)			53				22				31
Balance – end of period			21				209				209				187

Derivative warrant liabilities [member]

Statement Line Items [Line Items]

Disclosure of sensitivity analysis for actuarial assumptions [text block]

Warrant liabilities issued December 27, 2017
			March 31, 2018				March 31, 2017				February 28, 2017 (Unaudited)

Exercise price			US $1.26				—				—
Share price			US $1.02				—				—
Dividend			—				—				—
Risk-free interest			2.56	%			—				—
Estimated life (in years)			4.75				—				—
Expected volatility			95.16	%			—				—

Warrant liabilities issued December 3, 2013 1
			March 31, 2018				March 31, 2017				February 28, 2017 (Unaudited)

Exercise price			US $1.50				US $1.50				US $1.50
Share price (1)			US $1.02				US $1.36				US $1.25
Dividend			—				—				—
Risk-free interest			2.19	%			1.22	%			1.24	%
Estimated life (in years)			0.68				1.68				1.76
Expected volatility			133.86	%			108.35	%			107.36	%